Reported cryptic rearrangements of CBF␤-MYH11 in acute myeloid leukaemia are not due to false priming of contaminating DNA TO 
THE EDITOR
The presence of inv(16)(p13q22) at diagnosis of acute myeloid leukaemia (AML) is one of several good prognostic, cytogenetic indicators, 1 and such cytogenetic data are now used to stratify patient therapy (eg UK MRC AML 12 trial). The inv(16) chromosomal abnormality results in disruption of the CBF␤ gene and creation of the CBF␤-MYH11 fusion gene. 2 Transcripts from this fusion gene can be detected by RT-PCR and several groups, including ourselves, have shown that PCR techniques not only confirm positive cytogenetic findings for inv(16) but also allow detection of additional cases in which this translocation is not apparent. [3] [4] [5] [6] [7] In some cases, this is because the inv(16) abnormality is subtle and only detectable in good metaphase preparations, but in most cases these cryptic rearrangements are undetectable by high quality conventional cytogenetics. This finding has led us to suggest that all cases of AML should be screened for the presence of CBF␤-MYH11 fusion transcripts (and AML1-ETO transcripts). 3, 8 Recently Hackwell et al 9 reported a very high proportion of 'false positive' results using the primer sets from our study. They demonstrated that this is due to the 5Ј nested CBF␤ primer cross-hybridising with an intronic sequence of contaminating MYH11 genomic DNA, which results in the amplification of a 210 bp sequence from DNA of similar size to the expected 209 bp CBF␤-MYH11 RT-PCR product. This raised the possibility that the cryptic rearrangements reported by ourselves were spurious, and for this reason we have re-analysed 10 out of the 12 cases of cryptic rearrangement that we previously described. In the other two cases, there was no RNA for further analysis.
In each of these 10 cases, RT-PCR amplified a 209 bp band and no bands were produced from normal control RNA samples. Using genomic DNA from 10 individuals we were, however, able to confirm the production of a similar sized band. The PCR products from the 10 cases with purported cryptic CBF␤-MYH11 rearrangements, five cases of cytogenetically apparent inv(16) and five of the genomic DNA samples were then subjected to digestion with the restriction enzyme StuI. This enzyme will digest the product of a CBF␤-MYH11 fusion into two bands of 109 bp and 100 bp but the genomic DNAderived product does not contain any cutting sites. No digestion was observed in the genomic DNA-derived products, but complete digestion was observed in the five cases of inv(16) and all 10 cases of cryptic CBF␤-MYH11 rearrangements (Figure 1 ). In our original study, we confirmed the nature of the fusion product by sequencing across the breakpoint in three out of the 12 cases. We now carried out sequencing a further seven of these cases and identified the presence of a cryptic rearrangement in all of them.
This study thus confirms that cryptic rearrangements of CBF␤-MYH11 occur at a frequency sufficient to justify molecular screening of all cases of AML. The discrepancy between our finding of no 'false positive' results and the false positivity in approximately 80% of samples by Hackwell et al 9 is not immediately apparent. The same primer sets were used suggesting that false positives can arise due to excessive DNA contamination of RNA samples, inadequate stringency of annealing conditions or the use of excessive rounds of amplification. Regardless of the precise cause, the publication by Hackwell et al 9 emphasises the need to verify the identity of PCR products, particularly when there are apparent discrepancies between cytogenetic and molecular findings.
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